|
|
|
Anecortave Acetate Risk Reduction TrialThe University of Iowa Department of Ophthalmology and Visual Sciences is participating in the Anecortave Acetate Risk Reduction Trial. This is an exciting trial for eligible individuals with macular degeneration that have had vision loss in one eye. The goal of the study is to reduce the chance of vision loss in a patient's "good" eye. There are over 100 centers in the United States, Europe, Australia, and South America participating in the study. The target enrollment is 2,500 patients worldwide that will be followed for four years, receiving Anacortave Acetate every six months. Investigators at the University of Iowa intend to enroll 25 patients. Dr. Stephen Russell of the University of Iowa, Department of Ophthalmology & Visual
Sciences presented information for The Anecortave Acetate Risk Reduction Study
Group at the 2004 Association
for Research in Vision and Ophthalmology (ARVO)
meeting. The presentation was entitled "Anecortave Acetate Treatment of
'Dry' AMD to Reduce Risk of Progression to 'Wet' AMD - The Anecortave Acetate
Risk Reduction Trial (AART)." Stephen R. Russell, M.D. |
last updated 6-23-2004 |
|
